Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.0K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

806
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
806
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

749
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
749
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

260
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
260

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and Risk Factors of Diabetic Foot Syndrome in Patients Early After Pancreas or Kidney/Pancreas Transplantation and its Association with Preventive Measures.

The international journal of lower extremity wounds·2021
Same author

Changes in phenotypic patterns of blood monocytes after kidney transplantation and during acute rejection.

Physiological research·2021
Same author

Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis.

Physiological research·2021
Same author

Genetic Markers at ANRIL, FTO and 2q36.3 Locus in Czech Patients Undergoing Coronary Artery Bypass Graft Surgery.

Folia biologica·2021
Same author

Acute elevation of intraocular pressure in patient with hyperlipidemic myeloma.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2020
Same author

FAMILIAL HYPERCHOLESTEROLAEMIA - A DIAGNOSIS THAT EVERY PLASTIC SURGEON CAN EXPERIENCE.

Acta chirurgiae plasticae·2020
Same journal

The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.

Current atherosclerosis reports·2026
Same journal

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same journal

Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

Current atherosclerosis reports·2026
Same journal

Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

Current atherosclerosis reports·2026
Same journal

Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

Current atherosclerosis reports·2026
Same journal

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.1K

Statin Intolerance in Clinical Practice.

Michaela Snejdrlova1, T Altschmiedova2, M Vrablik2

  • 1Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University Prague, U nemocnice 1, 128 00, Praha, Czech Republic. Michaela.Snejdrlova@vfn.cz.

Current Atherosclerosis Reports
|June 5, 2020
PubMed
Summary
This summary is machine-generated.

Complete statin intolerance is often overestimated. A pilot study found most patients referred for statin intolerance could tolerate statin therapy with proper management, with rosuvastatin being the most tolerated.

Keywords:
Complete statin intolerancePartial statin intoleranceStatin associated muscle symptoms

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Related Experiment Videos

Last Updated: Dec 19, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.1K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Statin intolerance is a growing concern with increased statin use worldwide.
  • Factors influencing statin intolerance include genetics, drug interactions, and psychological elements.
  • True complete statin intolerance affects an estimated 3-6% of statin users.

Purpose of the Study:

  • To assess the actual prevalence of complete statin intolerance in patients referred to a specialized center.
  • To challenge the notion that complete statin intolerance is frequently overdiagnosed.
  • To demonstrate that tailored approaches can identify suitable statin treatments for most patients.

Main Methods:

  • Retrospective analysis of 300 patients with a history of statin intolerance.
  • Detailed diagnostic and therapeutic efforts were employed.
  • Patients were referred to the Center of Preventive Cardiology.

Main Results:

  • 74% (222 patients) successfully tolerated at least one statin.
  • 21% (63 patients) achieved their target lipid values.
  • Only 26% (78 patients) were confirmed as completely statin intolerant.
  • Rosuvastatin was the most frequently tolerated statin.

Conclusions:

  • Complete statin intolerance is likely overestimated and overdiagnosed.
  • A thorough, individualized approach can identify effective statin therapy for the majority of patients.
  • Specialized centers can successfully manage patients with perceived statin intolerance.